Ipca Laboratories Ltd

- No major capital expenditure plans except a solar project with a capital outlay of approximately INR 50 crores to use more green energy. - No current or future plans indicated for significant fundraising through debt or equity mentioned in the call transcript. - The company maintains healthy cash flows and had around INR 250 crores cash in the bank post land sale proceeds and other payments. - Overall, no mention of new debt or equity fundraising initiatives in the discussed period.

- No major expansion plans currently, except for a solar project focused on using more green energy. - The solar project has a capital expenditure outlook of approximately INR 50 crores. - No other significant capital expenditure plans announced at this time. - Strategic focus includes capability building in biosimilars, injectables, hormones, integrated manufacturing, and optimizing Unichem integration. - Biosimilar business has 5 candidates; technology transfer started for 2 products with manufacturing expected to start soon.

- Domestic business expected to grow at 10-12% annually, driven by branded formulations, CNS, neurology, and cardiology segments. - Export promotional branded business anticipated to grow steadily at 10-12% over the long term. - Generic business growth expected at 10-12%, with faster growth in Europe and U.S. markets. - U.S. market (Unichem business) projected to grow 8-10% annually over the next 2-3 years after regaining market share. - Ipca U.S. business plans to commercialize 4-5 new molecules annually; 7-8 commercialized in last years, with growth from backward-integrated molecules. - API business to have a slightly lower growth than formulations but improved in last quarters. - Biosimilar business with 5 candidates, manufacturing expected to start soon, contributing to future growth. - Overall company growth broadly expected around 10-11% in coming years.

- Unichem U.S. business expected to grow 7%-8% annually after regaining lost market share, driven by 4-5 new product launches over 2-3 years. (Page 14) - Unichem overall top-line growth guidance of 8%-10% over next 2-3 years post U.S. market share recovery. (Page 9, 14) - Promotional branded business (domestic and international) projected growth of 10%-12% over long term, supporting EBITDA margin expansion by ~1.5% per year. (Pages 12, 10) - Overall company growth targeted at 10%-11% with potential 300 bps EBITDA margin improvement over next two years excluding Unichem. (Page 10) - EBITDA margins expected to improve as higher-margin businesses grow, and as Unichem’s European capacity utilization increases. (Pages 7, 5) - R&D pipeline and filings expanding, including biosimilars, expected to enhance margins and profits future. (Page 6)

The transcript provided does not explicitly mention the current or expected order book or pending orders for Ipca Laboratories Limited. However, some relevant points related to business outlook and growth prospects are: - Unichem U.S. business expects to regain market share loss over 1-2 quarters and grow 8-10% over next 2-3 years. - Ipca U.S. portfolio has launched 5 molecules; 4-5 more expected in next 12-15 months, with 35 registrations pending. - Unichem filing and registration activities in Europe and ROW branded space expected to aid growth. - Domestic branded and promotional businesses are growing steadily with expanding margins. - Biosimilar business has 5 candidates, with technology transfer started for 2 products. - No specific order book or pending order numbers were disclosed during the call.